Summary
0.33 -0.01(-2.94%)09/06/2024
Panbela Therapeutics Inc (PBLA)
Panbela Therapeutics Inc (PBLA)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -10.81 | -12.00 | -13.16 | -13.61 | -70.21 | -77.55 | -93.71 | -96.73 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 0.33 | |
| Open | 0.33 | |
| High | 0.33 | |
| Low | 0.33 | |
| Volume | 1,081 | |
| Change | -0.04 | |
| Change % | -10.81 | |
| Avg Volume (20 Days) | 3,585 | |
| Volume/Avg Volume (20 Days) Ratio | 0.30 | |
| 52 Week Range | 0.30 - 8.20 | |
| Price vs 52 Week High | -95.98% | |
| Price vs 52 Week Low | 10.00% | |
| Range | 0.00 | |
| Gap Up/Down | -0.04 | |
Fundamentals | ||
| Market Capitalization (Mln) | 2 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 8.00 | |
| Book Value | 1.0020 | |
| Earnings Per Share | -0.6950 | |
| EPS Estimate Current Quarter | -0.2300 | |
| EPS Estimate Next Quarter | -0.1700 | |
| EPS Estimate Current Year | -0.7300 | |
| EPS Estimate Next Year | -0.7500 | |
| Diluted EPS (TTM) | -0.6950 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | -0.3947 | |
| Return on equity (TTM) | -0.6498 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.6964 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 13,434,200 | |
| Shares Float | 11,547,594 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 12.58 | |
| Institutions (%) | 12.01 | |
08/13 19:39 EST - seekingalpha.com
Panbela Therapeutics, Inc. (PBLA) Q2 2024 Earnings Call Transcript
Panbela Therapeutics, Inc. (OTCQB:PBLA) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants James Carbonara - Hayden, IR Jennifer Simpson - President and Chief Executive Officer Susan Horvath - Vice President and Chief Financial Officer Conference Call Participants Operator Good afternoon, everyone, and welcome to the Panbela Therapeutics Second Quarter 2024 Earnings Call. At this time, all participants have been placed on a listen-only mode.
Panbela Therapeutics, Inc. (PBLA) Q2 2024 Earnings Call Transcript
Panbela Therapeutics, Inc. (OTCQB:PBLA) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants James Carbonara - Hayden, IR Jennifer Simpson - President and Chief Executive Officer Susan Horvath - Vice President and Chief Financial Officer Conference Call Participants Operator Good afternoon, everyone, and welcome to the Panbela Therapeutics Second Quarter 2024 Earnings Call. At this time, all participants have been placed on a listen-only mode.
08/13 16:10 EST - globenewswire.com
Panbela Provides Business Update and Reports Q2 2024 Financial Results
MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET.
Panbela Provides Business Update and Reports Q2 2024 Financial Results
MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET.
07/30 16:15 EST - globenewswire.com
Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024
MINNEAPOLIS, July 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on Aug 13, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024.
Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024
MINNEAPOLIS, July 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on Aug 13, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024.
06/24 08:00 EST - globenewswire.com
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
MINNEAPOLIS, June 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its third pre-specified safety review of the ongoing Phase 3 ASPIRE clinical trial evaluating ivospemin in combination with gemcitabine and nab-Paclitaxel for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). The DSMB recommended study continuation without modification, marking the third consecutive positive safety review. The safety database now includes 395 patients, compared to 214 patients on November 29, 2023.
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
MINNEAPOLIS, June 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its third pre-specified safety review of the ongoing Phase 3 ASPIRE clinical trial evaluating ivospemin in combination with gemcitabine and nab-Paclitaxel for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). The DSMB recommended study continuation without modification, marking the third consecutive positive safety review. The safety database now includes 395 patients, compared to 214 patients on November 29, 2023.
05/20 01:36 EST - https://www.defenseworld.net
Panbela Therapeutics, Inc. (NASDAQ:PBLA) to Post Q2 2024 Earnings of ($2.07) Per Share, HC Wainwright Forecasts
Panbela Therapeutics, Inc. (NASDAQ:PBLA – Free Report) – Analysts at HC Wainwright dropped their Q2 2024 earnings per share estimates for Panbela Therapeutics in a research note issued to investors on Thursday, May 16th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($2.07) for the quarter, down from their prior estimate of ($1.28). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Panbela Therapeutics’ current full-year earnings is ($8.38) per share. HC Wainwright also issued estimates for Panbela Therapeutics’ Q3 2024 earnings at ($2.07) EPS, Q4 2024 earnings at ($1.98) EPS, FY2024 earnings at ($8.38) EPS, FY2025 earnings at ($3.75) EPS, FY2026 earnings at ($2.78) EPS and FY2027 earnings at ($1.01) EPS. Separately, Roth Mkm reissued a “buy” rating on shares of Panbela Therapeutics in a report on Wednesday, March 27th. Read Our Latest Research Report on Panbela Therapeutics Panbela Therapeutics Stock Performance Shares of PBLA stock opened at $0.44 on Monday. The stock’s 50-day simple moving average is $0.52 and its 200-day simple moving average is $5.94. The firm has a market capitalization of $1.53 million, a PE ratio of 0.00 and a beta of 1.55. Panbela Therapeutics has a fifty-two week low of $0.35 and a fifty-two week high of $243.06. Panbela Therapeutics (NASDAQ:PBLA – Get Free Report) last announced its quarterly earnings data on Tuesday, March 26th. The company reported ($65.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($24.34) by ($41.56). About Panbela Therapeutics (Get Free Report) Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. Read More Five stocks we like better than Panbela Therapeutics What Are Growth Stocks and Investing in Them MarketBeat Week in Review – 5/13 – 5/17 What is Forex and How Does it Work? Take-Two Interactive Software Offers 2nd Chance for Investors Using the MarketBeat Dividend Tax Calculator Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
Panbela Therapeutics, Inc. (NASDAQ:PBLA) to Post Q2 2024 Earnings of ($2.07) Per Share, HC Wainwright Forecasts
Panbela Therapeutics, Inc. (NASDAQ:PBLA – Free Report) – Analysts at HC Wainwright dropped their Q2 2024 earnings per share estimates for Panbela Therapeutics in a research note issued to investors on Thursday, May 16th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($2.07) for the quarter, down from their prior estimate of ($1.28). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Panbela Therapeutics’ current full-year earnings is ($8.38) per share. HC Wainwright also issued estimates for Panbela Therapeutics’ Q3 2024 earnings at ($2.07) EPS, Q4 2024 earnings at ($1.98) EPS, FY2024 earnings at ($8.38) EPS, FY2025 earnings at ($3.75) EPS, FY2026 earnings at ($2.78) EPS and FY2027 earnings at ($1.01) EPS. Separately, Roth Mkm reissued a “buy” rating on shares of Panbela Therapeutics in a report on Wednesday, March 27th. Read Our Latest Research Report on Panbela Therapeutics Panbela Therapeutics Stock Performance Shares of PBLA stock opened at $0.44 on Monday. The stock’s 50-day simple moving average is $0.52 and its 200-day simple moving average is $5.94. The firm has a market capitalization of $1.53 million, a PE ratio of 0.00 and a beta of 1.55. Panbela Therapeutics has a fifty-two week low of $0.35 and a fifty-two week high of $243.06. Panbela Therapeutics (NASDAQ:PBLA – Get Free Report) last announced its quarterly earnings data on Tuesday, March 26th. The company reported ($65.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($24.34) by ($41.56). About Panbela Therapeutics (Get Free Report) Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. Read More Five stocks we like better than Panbela Therapeutics What Are Growth Stocks and Investing in Them MarketBeat Week in Review – 5/13 – 5/17 What is Forex and How Does it Work? Take-Two Interactive Software Offers 2nd Chance for Investors Using the MarketBeat Dividend Tax Calculator Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
05/15 19:30 EST - seekingalpha.com
Panbela Therapeutics, Inc. (PBLA) Q1 2024 Earnings Call Transcript
Panbela Therapeutics, Inc. (OTC:PBLA) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants James Carbonara - IR, HaydenIR Jennifer Simpson - President & CEO Susan Horvath - CFO Conference Call Participants Jonathan Aschoff - Roth Capital Partners Operator Good afternoon, everyone, and welcome to the Panbela Therapeutics First Quarter 2024 Earnings Call. [Operator Instructions].
Panbela Therapeutics, Inc. (PBLA) Q1 2024 Earnings Call Transcript
Panbela Therapeutics, Inc. (OTC:PBLA) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants James Carbonara - IR, HaydenIR Jennifer Simpson - President & CEO Susan Horvath - CFO Conference Call Participants Jonathan Aschoff - Roth Capital Partners Operator Good afternoon, everyone, and welcome to the Panbela Therapeutics First Quarter 2024 Earnings Call. [Operator Instructions].
05/15 16:10 EST - globenewswire.com
Panbela Provides Business Update and Reports Q1 2024 Financial Results
MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended March 31, 2024. As previously announced, management is hosting earnings call today at 4:30 p.m. ET.
Panbela Provides Business Update and Reports Q1 2024 Financial Results
MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended March 31, 2024. As previously announced, management is hosting earnings call today at 4:30 p.m. ET.
05/06 08:00 EST - globenewswire.com
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced an Issue Notification for the US continuation patent US 11,925,613 B2 and Canadian patent CA 3003149 titled “EFLORNITHINE AND SULINDAC, A FIXED DOSE COMBINATION FORMULATION”. These patents claim a novel composition of a fixed dose combination of eflornithine and sulindac, which is called Flynpovi.
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced an Issue Notification for the US continuation patent US 11,925,613 B2 and Canadian patent CA 3003149 titled “EFLORNITHINE AND SULINDAC, A FIXED DOSE COMBINATION FORMULATION”. These patents claim a novel composition of a fixed dose combination of eflornithine and sulindac, which is called Flynpovi.
05/01 16:15 EST - globenewswire.com
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 15, 2024, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2024.
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 15, 2024, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2024.
04/30 08:00 EST - globenewswire.com
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for eflornithine, an inhibitor of polyamine synthesis, has been accepted for an oral presentation at the Digestive Disease Week (DDW) conference, which will be held May 18-21, 2024. The work reflects the Company's on-going collaboration with Vanderbilt University Medical Center.
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for eflornithine, an inhibitor of polyamine synthesis, has been accepted for an oral presentation at the Digestive Disease Week (DDW) conference, which will be held May 18-21, 2024. The work reflects the Company's on-going collaboration with Vanderbilt University Medical Center.
04/22 08:00 EST - globenewswire.com
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
Trial's lower-than-expected event rate suggests improved survival outcomes Trial's lower-than-expected event rate suggests improved survival outcomes
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
Trial's lower-than-expected event rate suggests improved survival outcomes Trial's lower-than-expected event rate suggests improved survival outcomes
04/18 08:00 EST - globenewswire.com
Panbela Announces Poster Presentation at American Association for Cancer Research:
Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models
Panbela Announces Poster Presentation at American Association for Cancer Research:
Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models
04/16 17:29 EST - globenewswire.com
Panbela Announces Transfer to OTCQB Market
MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that its common stock has been approved for quotation on the OTCQB market. Panbela's common stock will be eligible for quotation on the OTCQB starting on April 17, 2024, under the symbol “PBLA.”
Panbela Announces Transfer to OTCQB Market
MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that its common stock has been approved for quotation on the OTCQB market. Panbela's common stock will be eligible for quotation on the OTCQB starting on April 17, 2024, under the symbol “PBLA.”
03/26 21:49 EST - seekingalpha.com
Panbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Call Transcript
Panbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Call Transcript
Panbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Call Transcript
Panbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Call Transcript
03/26 16:10 EST - globenewswire.com
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
MINNEAPOLIS, March 26, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter and full year ended December 31, 2023. As previously announced, management is hosting earnings call today at 4:30 p.m. ET.
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
MINNEAPOLIS, March 26, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter and full year ended December 31, 2023. As previously announced, management is hosting earnings call today at 4:30 p.m. ET.
03/12 16:15 EST - globenewswire.com
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on March 26, 2024, at 4:30 PM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2023.
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on March 26, 2024, at 4:30 PM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2023.
02/23 07:50 EST - benzinga.com
Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
02/15 08:00 EST - globenewswire.com
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
MINNEAPOLIS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that, has regained compliance with applicable listing standards of The Nasdaq Stock Market (“Nasdaq”) for bid price and publicly held shares.
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
MINNEAPOLIS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that, has regained compliance with applicable listing standards of The Nasdaq Stock Market (“Nasdaq”) for bid price and publicly held shares.
02/01 07:00 EST - globenewswire.com
Panbela Announces Closing of Approximately $9.0 Million Public Offering
MINNEAPOLIS, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the closing of its previously announced public offering of (i) 4,375,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) two classes of warrants to purchase up to an aggregate of 8,750,000 shares of its common stock (the “Public Warrants”) at a purchase price of $2.06 per share and associated Public Warrants and $2.059 per pre-funded warrant and associated Public Warrants. The pre-funded warrants have an exercise price of $0.001 per share. The Public Warrants have an exercise price of $2.06 per share, are exercisable upon issuance, and will expire five years following the date of issuance. The Public Warrants do not have any alternative cashless exercise or other provisions to adjust their exercise price beyond customary proportionate adjustments for recapitalizations and similar events.
Panbela Announces Closing of Approximately $9.0 Million Public Offering
MINNEAPOLIS, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the closing of its previously announced public offering of (i) 4,375,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) two classes of warrants to purchase up to an aggregate of 8,750,000 shares of its common stock (the “Public Warrants”) at a purchase price of $2.06 per share and associated Public Warrants and $2.059 per pre-funded warrant and associated Public Warrants. The pre-funded warrants have an exercise price of $0.001 per share. The Public Warrants have an exercise price of $2.06 per share, are exercisable upon issuance, and will expire five years following the date of issuance. The Public Warrants do not have any alternative cashless exercise or other provisions to adjust their exercise price beyond customary proportionate adjustments for recapitalizations and similar events.
01/30 08:15 EST - globenewswire.com
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
MINNEAPOLIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for SBP-101, a proprietary polyamine analogue, has been accepted for poster presentation at the American Association for Cancer Research (AACR), which will be held April 5-10, 2024. The work reflects the Company's on-going collaboration with Johns Hopkins University School of Medicine.
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
MINNEAPOLIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for SBP-101, a proprietary polyamine analogue, has been accepted for poster presentation at the American Association for Cancer Research (AACR), which will be held April 5-10, 2024. The work reflects the Company's on-going collaboration with Johns Hopkins University School of Medicine.